The paid-up equity capital of the company is less than Rs. 10 crores and Networth is less than Rs. 25 crores as on 31/03/2023, 31/03/2024, 31/03/2025, the requirement u/r 27(2) of SEBI ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gujarat Terce Laboratories has informed BSE that the Corporate Governance Report requirement under Regulation 27(2) of SEBI LODR does not apply to it for the quarter ended June 30, 2025. This is because its paid-up equity capital (Rs. 7.42 crores) has been below the Rs. 10 crore threshold and its net worth (Rs. 6.48 crores in FY25, Rs. 7.10 crores in FY24, Rs. 6.86 crores in FY23) has been below the Rs. 25 crore threshold for the last three financial years. The share count has remained steady at 74,20,300 equity shares across all three years. Notably, the company's reserves are negative in every reported year (Rs. -1.29 cr in FY25, Rs. -0.31 cr in FY24, Rs. -0.56 cr in FY23), indicating accumulated losses.
This is a routine compliance filing with no direct effect on shareholders — the company is simply availing an exemption available to small-cap listed entities. However, the consistently negative reserves and eroding net worth (from Rs. 7.10 cr to Rs. 6.48 cr in a year) signal weak financial health, which investors should monitor.